


6 Conferences, ONE Location!

April 17-18



The Challenge of Antibacterial Drug Development



Fragment-Based Drug Discovery




Anti-Inflammatories: Small Molecule Approaches


April 18-19



Physicochemical Drug Properties



Protein-Protein Interactions as Drug Targets



HCV Drug Discovery Targeting Viral and Host Proteins

Cambridge Healthtech Institute's Seventh Annual

Drug Discovery Chemistry

April 17-19, 2012 | Hilton San Diego Resort & Spa | San Diego, CA

Event Highlights

Physicochemical Drug Properties — **NEW!**

Targeted Short Courses

Panel & Roundtable Discussions

Over 70 Presentations

Scientific Posters

Exhibit Hours

Keynote Presentations

Networking Reception

Event at a Glance

Tuesday, April 17	The Challenge of Antibacterial Drug Development	Fragment-Based Drug Discovery	Anti-Inflammatories: Small Molecule Approaches
Wednesday, April 18, a.m.	The Challenge of Antibacterial Drug Development	Fragment-Based Drug Discovery	Anti-Inflammatories: Small Molecule Approaches
Wednesday, April 18, p.m.	Physicochemical Drug Properties	Protein-Protein Interactions as Drug Targets	HCV Drug Discovery Targeting Viral and Host Proteins
Thursday, April 19	Physicochemical Drug Properties	Protein-Protein Interactions as Drug Targets	HCV Drug Discovery Targeting Viral and Host Proteins

Corporate Sponsors



intelligent chemistry for lead discovery & lead optimization



Lead Sponsoring Publications:

Bio-IT World

TheScientist
MAGAZINE OF THE LIFE SCIENCES



GEN Genetic Engineering & Biotechnology News

Additional Sponsoring Publications:

PharmaVOICE



nature

Combinatorial Chemistry & High Throughput Screening
www.bsipubl.demon.co.uk/cchts



Short Courses*

Monday, April 16

12:00-3:00pm

SC 1 Screening for Allosteric Modulators

The advancing technology of high-throughput screening is changing the type of molecules found. With protein function more physiologically relevant, the quality of the molecules that pharmacologists and medicinal chemists must deal with is changing. This course will familiarize researchers with the tools needed to exploit this potentially fruitful area of new drug discovery through discussion of allosteric molecules, detection of allostery, and quantifying allostery for chemical lead optimization. The course is designed to answer these questions:

- What is protein allostery?
- What makes allosteric molecules unique and how can this contribute to unique therapeutic properties?
- How can we detect allostery?
- How to quantify allostery for chemical lead optimization?

Course Instructor:

Terry P. Kenakin, Ph.D., Professor, Department of Pharmacology, University of North Carolina School of Medicine

SC 2 The Basics of Surface Plasmon Resonance

Topics will include:

- Applications of SPR
- Covalent vs Non-Covalent Immobilisation
- Data Analysis
- Pro's and Con's

Instructors to be Announced

Monday, April 16

3:30-6:30pm

SC 3 Advanced Tools and Technologies for Fragment-Based Design

This short course will cover the basic ideas behind fragment discovery, outline the major tools for discovering fragments, and provide case studies in the optimization of fragments to drug leads.

Course Instructor:

Daniel A. Erlanson, Ph.D., Co-Founder, Carmot Therapeutics, Inc.

Additional instructors to be announced

SC 4 Cheminformatics for the Medicinal Chemist

Topics will include:

- Cheminformatics for FBDD
- Lead-Like Screening Assays
- The Concept of Lead-Likeness
- Virtual Screening
- Improving Hit Quality

Instructors to be Announced

SC 5 Pre-clinical Toxicity for Chemists: New Assays, New Info

Topics will include:

- Predictive chemistry and toxicology
- Understanding your biologist -- new demands for organ predictive toxicity, e.g. cardiac and liver
- Tools of the trade -- exploiting chemical modifications

Wednesday, April 18

6:30-9:00pm

DINNER SHORT COURSE:

SC 6 HCV and the Host Immune System

Topics will include:

- Review of HCV infection cycle and human immune response
- Targets and drug candidates for boosting immune response to HCV
- Replacing interferon

**Separate registration required*




For quite some time now, the lack of new antibacterials has been broadly recognized as a major unmet medical need. To successfully tackle antibacterial resistance, screening for novel targets and developing new strategies to interfere with bacteria are just as important as other challenges, including predicting toxicology, selectivity, resistance, permeability and pk of a new lead, and creating new models for optimization of leads and compounds. This conference is designed to bring together executive level scientists from the academic, pharmaceutical and biotech areas to discuss progress, novel insight, lessons learned and current bottlenecks.

TUESDAY, APRIL 17**7:00 am Registration and Morning Coffee****8:00 Chairperson's Opening Remarks****» 8:10 KEYNOTE PRESENTATION****Lessons Learned: When it Comes to Drug Discovery Not All Gram-Negatives are Created Equal***Herbert Schweizer, Ph.D., Professor, Microbiology, Immunology and Pathology, Colorado State University***GYRASE/ TOPOISOMERASE INHIBITORS****8:50 Dual-Targeting DNA Supercoiling Inhibitors for the Treatment of Bacterial Infections***Jim Palmer, Ph.D., Director, Drug Discovery, Research, Biota Holdings, Ltd.***9:20 The Discovery of Potent, Dual Targeting Pyrrolopyrimidine Inhibitors of Bacterial DNA Gyrase B and Topoisomerase IV with Broad Spectrum Antibacterial Activity***John Finn, Ph.D., CSO, R&D, Trius Therapeutics***9:50 Networking Coffee Break****TARGETING MRSA****10:15 Microbiological and Pharmacodynamic Interactions of Avibactam with the Anti-MRSA Cephalosporin Ceftaroline***Ian Critchley, Ph.D., Vice President, Microbiology, Cerexa, Inc.***10:45 Identification of Novel Drug Targets by Exploitation of Indel-Based Structural Differences in Highly Conserved Proteins: Pyruvate Kinase as a Test Case***Roya Zoraghi, Ph.D., Research Scientist and Director of Screening, Indel Therapeutics***11:15 Sponsored Presentation (Opportunity Available)****LEAD DEVELOPMENTS****11:30 Antibacterial Oxazolidinones: A Historical Perspective and Recent Developments***Mike Gordeev, Ph.D., CSO, MicuRX Pharmaceuticals***12:00 pm Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own****1:25 Chairperson's Remarks****1:30 Safe Drugs to Kill Bad Bugs — Evolva's Novel Topoisomerase Inhibitors***Jutta Heim, Ph.D., Professor, Biotechnology; CSO, Discovery, Evolva SA***2:00 Developing Bacteriophage Based Antibiotics***David Harper, Ph.D., CSO, AmpliPhi***2:30 ASINEX Inverse MedChem Approach: Amphiphilic Small Natural-Product Like Compounds for Probing the Antibacterial Area***Roman Kombarov, Ph.D., Project Manager, ASINEX***3:00 Sponsored Presentation (Opportunity Available)****3:15 Networking Refreshment Break in Exhibit Hall with Poster Viewing****4:00 PK/PD and Emergence of Resistance***Ursula Theuretzbacher, Ph.D., Center for Anti-Infective Agents (CEFAIA)***4:30 The Design of High-Frequency Transposition for Determining Antibacterial Mode of Action***Timothy Meredith, Ph.D., Merck***5:00 Talk Title to be Announced***Stefan Miller, Ph.D., CEO, Lisando GmbH*

Sponsored by

**5:30 Networking Reception in the Exhibit Hall with Poster Viewing****6:30 End of Day****WEDNESDAY, APRIL 18****7:45 am Continental Breakfast Breakout Discussions****CURRENT STRATEGIES FOR STAYING AHEAD OF THE CURVE****8:55 Chairperson's Opening Remarks****9:00 Development of Novel Antibiotic Candidates: Redesigning Tetracyclines by Convergent Assembly of Building Blocks***Joyce Suttcliffe, Ph.D., Senior Vice President, Biology, Tetrphase Pharmaceuticals, Inc.***9:30 Gaining Insights into Molecular Targets of β -Lactam Antibiotics in Gram-Negative Pathogens***Seungil Han, Ph.D., Senior Principal Scientist, Pfizer, Inc.***10:00 Networking Coffee Break in the Exhibit Hall with Poster Viewing****10:45 Sponsored Presentation (Opportunity Available)****11:00 POL7080 – A Novel Pseudomonas Specific Antibiotic for Treatment of Severe Infections***Klaus Dembowski, M.D., Ph.D., Head, Drug Discovery and Development, CMO, Polyphor Ltd.***11:30 CRS3123, a Novel Agent for Treatment of Clostridium Difficile Infection***Thale Jarvis, Ph.D., Vice President, R&D, Crestone, Inc.***12:00 pm End of Conference**



Finding fragments by various screening methods has become an established practice. Each of the technologies used have a different set of advantages and disadvantages. Questions such as how to select the most suitable projects, how and when to use screening methods such as crystallography, NMR, SPR or mass spec either as a standalone technique or in combination and how to correctly predict binding at active sites will be addressed in this meeting. In addition, new challenges are arising and will be discussed, such as fragment docking, fragment library design, ligand efficiency, fragment selectivity and specificity.

TUESDAY, APRIL 17**7:00 am Registration and Morning Coffee****8:00 Chairperson's Opening Remarks****» 8:10 KEYNOTE PRESENTATION***Maurizio Pellecchia, Ph.D., Professor, Burnham Institute for Medical Research***SCREENING OF FRAGMENTS****8:50 Virtual Screens of Fragments against a Panel of HIV Protease Variants on FightAIDS@Home Discovered Two Novel Inhibitors***Alex L. Perryman, Ph.D., Research Associate, Professor Art Olson's Molecular Graphics Lab, Department of Molecular Biology, The Scripps Research Institute***9:20 Talk Title to be Announced***Rodderick Hubbard, Ph.D., Vernalis Ltd.***9:50 Networking Coffee Break****NMR****10:15 Using New Tools for an Old Target: Finding Active Ligands to a Novel Binding Site in Kras Using Solution State NMR***Till Maurer, Senior Scientist, Structural Biology, Genentech, Inc.***10:45 You Want to Put Your Fragment Where? Targeting the Next (And Really Hard!) Generation of Targets***Edward Zartler, Ph.D., President & CSO, Quantum Tessera Consulting, LLC and ZoBio***11:15 The CEfrag™ Screen: Fragment Screening using Capillary Electrophoresis***Carol Austin, Ph.D., Biology Group Leader, Selcia*

Sponsored by

**CURRENT STRATEGIES AND FUTURE FIELDS****11:30 What Makes a Good Fragment – Ligand Efficiency, Structure, Novelty, Chemical Tractability, SAR***Daniel Erlanson, Ph.D., Co-Founder, Carmot Therapeutics, Inc.***12:00 pm Luncheon Presentation** (*Sponsorship Opportunity Available*) **or Lunch on Your Own****1:25 Chairperson's Remarks****1:30 Selectivity in Fragment-Based Drug Discovery***Marcel Verdonk, Ph.D., Director, Computational Chemistry and Informatics, Astex Therapeutics, Inc.***2:00 Thermodynamic Analysis for Ligand Binding Modes and Its Use for FBDD***Iwan de Esch, Ph.D., Associate Professor, Medicinal Chemistry, VU University Amsterdam***2:30 REPLACE Fragment-Based Strategy***Campbell McInness, Ph.D., Associate Professor, Medicinal Chemistry, University of South Carolina***3:00 Sponsored Presentation** (*Opportunity Available*)**3:15 Networking Refreshment Break in Exhibit Hall with Poster Viewing****BACE INHIBITORS****4:00 Multidisciplinary Approach to Optimization of Weak Benzimidazole BACE1 Fragment Hits***Ivan Efremov, Ph.D., Senior Principal Scientist, Neurosciences Chemistry, Worldwide Medicinal Chemistry, Pfizer, Inc.***4:30 Fragment-Based Design and Clinical Translation of BACE Inhibitors***David Timm, Ph.D., Chemist, Neuroscience, Lilly Research Laboratories***5:00 Identification of an *in vivo* Efficacious BACE1 Inhibitor Derived From Fragment Screening***Ted Judd, Ph.D., Senior Scientist, Amgen, Inc.***5:30 - 6:30 Networking Reception in the Exhibit Hall with Poster Viewing****WEDNESDAY, APRIL 18****7:45 am Continental Breakfast Breakout Discussions****APPLIED FBDD****8:55 Chairperson's Opening Remarks****9:00 Talk Title to be Announced***Seth Cohen, Ph.D., Professor, Chemistry and Biochemistry, University of California, San Diego***9:30 Computational Methods in Fragment-Based Drug Design***Chris Williams, Ph.D., Principal Scientist, Chemical Computing Group*

Sponsored by

**10:00 Networking Coffee Break in the Exhibit Hall with Poster Viewing****10:45 Sponsored Presentation** (*Opportunity Available*)**11:00 Enteropeptidase: Identifying and Validating a Novel Target for the Treatment Obesity and Type II Diabetes by Rational Drug Design***Itzik Harosh, Ph.D., CSO, Drug Discovery, ObeTherapy***11:30 Development of Novel High-Throughput Assay for PCSK9 Inhibitor for Atherosclerosis and Coronary Heart Disease Treatment***Weiming Xu, Senior Research Associate, Ph.D., Molecular Biology and Biotechnology, University of Sheffield***12:00 pm End of Conference**



JAK kinase inhibitors will probably be the first new class of oral anti-inflammatories on the market, with the first one likely to receive approval end of 2012. But which JAK or combinations of JAK enzymes is going to prove the best to inhibit in terms of side effects and overall risk benefit profile to patients? How are the other kinase inhibitors aimed at targeting SYK and BTK, targeted for autoimmune disease but with broader potential in diseases such as cancer, progressing?

TUESDAY, APRIL 17**7:00 am Registration and Morning Coffee**

ORAL ANTI-INFLAMMATORY DRUG CANDIDATES (BESIDES KINASE INHIBITORS)

8:00 Chairperson's Opening Remarks

Martin Braddock, Ph.D., Senior Scientist, Global Project Leadership, AstraZeneca R&D

» 8:10 KEYNOTE PRESENTATION

Immunology/Inflammation Overview – Targets of Biologics and Small Molecules

Paul Garside, Ph.D., Professor, Immunology, University of Glasgow

8:50 Pre-Clinical and Clinical Profile of the Dual S1P1/S1P5 Modulator BAF312, in Development for the Treatment of Multiple Sclerosis

Barbara Nuesslein-Hildesheim, Ph.D., Director, Autoimmunity, Transplantation & Inflammation Disease Area, Novartis Institutes for BioMedical Research

9:20 Discovery and Early Clinical Development of ARRY-502 a CRTh2/DP2 Antagonist for the Treatment of Allergic Inflammation

David Chantry, Ph.D., Senior Director, Cellular and Translational Biology, Array Biopharma

9:50 Networking Coffee Break

10:15 Dissociated Agonist of Gluco-corticoid Receptor: Pre-Clinical and Clinical Development of a Selective Glucocorticoid Anti-Inflammatory

Suvit Thaisrivongs, Ph.D., Vice President, Chemistry, Pfizer

10:45 The Role of the Inflammatory Enzyme C2GNT in Diabetic Retinopathy: Journey from Lab to Clinical Application

Rakesh Chibber, Ph.D., Senior Lecturer, Institute of Biomedical and Clinical Science, Peninsula College of Medicine and Dentistry, University of Exeter and Plymouth

11:15 Sponsored Presentation (Opportunity Available)**11:30 Talk Title to be Announced**

Anne Fourie, Ph.D., Director, Immunology, Johnson & Johnson

12:00 pm Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

1:00 Session Break

JAK AND SYK INHIBITORS FOR INFLAMMATION

1:25 Chairperson's Remarks

Rajinder Singh, Ph.D., Vice President, Medicinal Chemistry, Rigel Pharmaceuticals

1:30 Discovery and Development Update on Tofacitinib

Mark Flanagan, Ph.D., Senior Principal Scientist, Worldwide Medicinal Chemistry, Pfizer

2:00 Development of JAK inhibitor, AC430, for Inflammation-Related Conditions

Robert C. Armstrong, Ph.D., Executive Director of Pharmacology, Ambit Biosciences Corporation

2:30 Discovery of a Potent Syk Kinase Inhibitor R343 as a Treatment for Allergic Asthma

Esteban Masuda, Ph.D., Vice President, Immunology, Rigel Pharmaceuticals

3:00 Selection of Safer and More Effective Anti-Inflammatory Kinase Inhibitors Using a Platform of Primary Human Cell Based Disease Models (BioMAP® systems)

Ellen Berg, Ph.D., GM and CSO, BioSeek, LLC



3:15 Networking Refreshment Break in Exhibit Hall with Poster Viewing

PROBING INFLAMMATION

4:00 Discovery and Development of Novel Small Molecule Inhibitors of HDAC and PI3K Isoforms for the Treatment of Immune-Inflammatory Disease

Stephen Shuttleworth, Ph.D., CSO, Karus Therapeutics

4:30 Panel Discussion: Stargazing? Progress in Probing Inflammation Early

Moderator: Martin Braddock, Ph.D., Senior Scientist, Global Project Leadership, AstraZeneca R&D

5:00 Presentation to be Announced**5:30 Networking Reception in Exhibit Hall, Poster Viewing****6:30 End of Day****WEDNESDAY, APRIL 18****7:45 am Continental Breakfast Breakout Discussions**

BTK AND OTHER KINASE INHIBITORS FOR INFLAMMATION

8:55 Chairperson's Opening Remarks

9:00 Small Molecule BTK Inhibitors: An Update from Pharmacoclycs

Wei Chen, Ph.D., Associate Director, Medicinal Chemistry, Pharmacoclycs, Inc.

9:30 BTK from Bench to Bedside: Covalently Silencing B Cells with AVL-292

Deqiang Niu, Ph.D., Associate Director Medicinal Chemistry, Avila Therapeutics

10:00 Networking Coffee Break in the Exhibit Hall with Poster Viewing

10:45 Sponsored Presentation (Opportunity Available)


11:00 Update on Targeting IκKinase for Inflammation

Bill Pitts, Ph.D., Group Leader, Medicinal Chemistry, Bristol Myers Squibb

11:30 IκKbeta Inhibitor Program

Erick Young, Ph.D., Senior Research Fellow, Medicinal Chemistry, Boehringer Ingelheim

12:00 pm End of Conference



The optimization of physical properties of a compound is fundamental to the drug discovery process, mainly due to their influence on absorption and distribution *in vivo*. This provides insight into the *in vivo* transport processes and knowing the properties will help with choosing the optimal compounds for the task. It saves costs and time when compounds are being properly analyzed in the design stage before they are moving into development, as it is important to consider questions such as how hydrophobicity will affect the solubility of a drug down the line or how the charge of the compound interacts with the absorption by a transport mechanism. Also, the use of predictive models is important, but again, without consideration of the actual physical chemical property of the new compound, the analyses will be based on a different set of data. This meeting will discuss what it takes to create selective and efficacious compounds and to understand the biological data by analyzing the physicochemical properties early on.

WEDNESDAY, APRIL 18**12:30 pm Registration****1:30 Chairperson's Opening Remarks****THE PATH AHEAD****1:40 Getting Physical in Drug Discovery; Where Next for Property Profiling and Predictive Methods?***Robert J. Young, Ph.D., GlaxoSmithKline***2:55 Getting Physical in Drug Discovery: A Suite of Physicochemical Methods to Enable Successful Drug Discovery***Alan P. Hill, Ph.D., Team Leder, PhysChem, Department of Analytical Chemistry, GlaxoSmithKline, Stevenage UK***3:10 Sponsored Presentations** (Opportunity Available)**3:40 Networking Refreshment Break in Exhibit Hall with Poster Viewing****INTERPRETING DATA****4:20 Presentation to be Announced****4:50 The Intricacies of Interpreting Pharmaceutical Data**
*Teri Stouch, Ph.D., President, R&D, Science for Solutions, LLC***5:20 Breakout Discussions****6:30 End of Day****THURSDAY, APRIL 19****7:30 am Breakfast Workshop Presentation** (Sponsorship Opportunity Available) **or Morning Coffee****8:15 Chairperson's Opening Remarks****» 8:10 KEYNOTE PRESENTATION****DELIVERING EFFICACIOUS COMPOUNDS****9:00 Integration of Structure Based Drug Design (SBDD) & Physicochemical Properties-Based Analysis and Design Approaches to Drive Multiparameter Optimization to Deliver Improved Cancer Drug Candidates***Martin Edwards, Ph.D., Vice President and Head of Oncology Medicinal Chemistry, Pfizer***9:30 Thermodynamically Derived Rules for Affinity and Selectivity Optimization of Drug Candidates***Ernesto Freire, Ph.D., Henry Walters Professor, Johns Hopkins University***10:00 Networking Coffee Break in the Exhibit Hall with Poster Viewing****COMPUTATIONAL DESIGN****10:45 Designing Molecules that Survive in Neuroscience Medicinal Chemistry: CNS MPO Desirability***Xinjun Hou, Ph.D., Associate Research Fellow, Neuroscience Computational Chemistry, Pfizer***11:15 Protein Structure and Sequence Mining for Improving Computational Design of Stable Proteins***Janwen Fang, Ph.D., Associate Scientist, Director, Applied Bioinformatics Laboratory, The University of Kansas***11:45 Speaker to be Announced****12:15 pm Sponsored Presentation** (Opportunity Available)**12:30 Walk and Talk Luncheon in the Exhibit Hall (Last Chance for Poster and Exhibit Viewing)****1:55 Chairperson's Remarks****2:00 Panel Discussion: Is there a "Too Early" to Consider the Physics?***Moderator: Teri Stouch, Ph.D., President, R&D, Science for Solutions, LLC***3:00 Networking Refreshment Break****OPTIMIZING COMPOUNDS BY UNDERSTANDING PHYSICO-CHEMICAL PROPERTIES****3:20 Presentation to be Announced****3:50 Attributes of Physico-Chemical Properties of Successful Drug Candidates***Li Di, Ph.D., Associate Research Fellow, Pfizer, Inc.***4:20 Talk Title to be Announced***Michael A. Walker, Ph.D., Bristol-Myers Squibb Pharmaceutical Research Institute (tentative)***4:50 End of Conference**

In its fifth year, CHI's conference is covering the journey from identifying PPI interaction pairs all the way to successfully developing a PPI inhibitor. Along the way, many questions need to be answered and obstacles need to be addressed such as challenges the binding sites are presenting, modulation of PPI, predicting PPI modes identifying novel inhibitors and what can be done to target PPI successfully.

WEDNESDAY, APRIL 18**12:30 pm Registration****THERAPEUTIC APPLICATIONS****1:30 Chairperson's Opening Remarks****1:40 Targeting FOXM1/NPM Interactions against Cancer***Andrei Gartel, Ph.D., Associate Professor, Medicine, University of Illinois***2:10 Cognition Enhancement by Disruption of NR2B-Cdk5 Interactions by a Small Interfering Peptide Drug***James Bibb, Associate Professor, Psychiatry and Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center***2:40 Mimicking the Hotspots at Protein-Protein Interfaces***Lidio Meireles, Ph.D., Scientist, Vertex Pharmaceuticals***3:10 Antibody Screening and Characterization Using Multiplexed SPR***Ruben Luo, Ph.D., Product Manager, Bio-Rad Laboratories*Sponsored by
BIO-RAD**3:25 Capillary Electrophoresis : an Ideal Solution-Based Method for Monitoring Protein-Protein Interactions***Carol Austin, Ph.D., Biology Group Leader, Selcia*Sponsored by
selcia**3:40 Networking Refreshment Break in Exhibit Hall with Poster Viewing****DRUGGABILITY OF PPI****4:20 Finding Druggable Hot Spots in Protein-Protein Interfaces***Sandor Vajda, Ph.D., Professor, Biomedical Engineering and Chemistry, Boston University***4:50 An Example of Challenging Chemical Space: Protein-Protein Interfaces***Philippe Roche, Ph.D., Senior Scientist, Cancer Research, CNRS***5:20 Breakout Discussions****6:30 End of Day****THURSDAY, APRIL 19****7:30 am Breakfast Presentation** (Sponsorship Opportunity Available) **or Morning Coffee****8:15 Chairperson's Opening Remarks****» 8:20 KEYNOTE PRESENTATION****Chemical Design Principles for the Discovery of Inhibitors of Protein-Protein Interactions***Kim D. Janda, Ph.D., Professor, Departments of Chemistry and Immunology, Ely R. Callaway, Jr. Chair in Chemistry Director, Worm Institute of Research and Medicine (WIRM); Associate Editor: Bioorganic & Medicinal Chemistry, The Scripps Research Institute***9:00 The Discovery of Chromenotriazolopyrimidines: Potent Inhibitors of the MDM2-p53 Protein-Protein Interaction***Hilary Plake Beck, Ph.D., Senior Scientist, Amgen, Inc.***9:30 Talk Title to be Announced***Michelle Arkin, Ph.D., University of California San Francisco***10:00 Networking Coffee Break in the Exhibit Hall with Poster Viewing****NOVEL TOOLS APPLIED TO PPI****10:45 Protein Docking and Conformational Properties of the Interfaces***Ilya Vakser, Ph.D., Director and Professor, Bioinformatics, University of Kansas***11:15 ASINEX Approaches to the Protein-Protein Interaction (PPI) Area – From Spiro-Fused Saturated Skeletal Diversity to Peptide Mimetics***Andrea Altieri, Ph.D., Tailored Compound Set Support Manager, ASINEX***11:45 A Leap into the Chemical Space of Protein-Protein Interaction Inhibitors***Oliver Sperandio, Ph.D., Senior Research Associate, INSERM***12:15 pm Sponsored Presentation** (Opportunity Available)**12:30 Walk and Talk Luncheon in the Exhibit Hall (Last Chance for Poster and Exhibit Viewing)****1:55 Chairperson's Remarks****2:00 On-Demand Microarray to Study Protein-Protein Interactions***Deb K. Chatterjee, Ph.D., Associate Director & Senior Principal Scientist, Protein Expression Laboratory, SAIC-Frederick, Inc., National Cancer Institute at Frederick***2:30 Sponsored Presentation** (Opportunity Available)**3:00 Networking Refreshment Break****3:20 Identification and Characterization of Protein-Protein Interaction Inhibitors***Laura Silvan, Ph.D., Crystallography, Department of Molecular Discovery, Biogen Idec***3:50 Substrate-Envelope Approach - A Novel Structure-Based Tool for Design of Highly Specific Drugs for Promiscuous Targets***Moses Prabu, Ph.D., Assistant Professor, Division of Basic Sciences, The Commonwealth Medical College***4:20 Speaker to be Announced****5:50 End of Conference**

Sponsored by



Intelligent chemistry for lead discovery & optimization



The newest therapies in more than a decade for people infected with the Hepatitis C virus (HCV) have recently hit the market. Hear about the chemistry of this new class of protease inhibitors and progress on 2nd generation versions, as well as updates on the clinical progress and chemical optimizations of other direct acting antivirals (DAAs). An emphasis will be on progress of various combinations of the new DAAs, especially in the context of an ideal interferon-free regimen. Newer anti-HCV drug candidates, including those that target host/virus interactions will also be covered.

WEDNESDAY, APRIL 18**12:30 pm Registration****TARGETING THE HOST AND 'NEWER' HCV PROTEINS****1:30 Chairperson's Opening Remarks****1:40 Update on Development of Cyclophilin Inhibitor(s) for Combating HCV***Kai Lin, Ph.D., Group Head, Virology, Novartis***2:10 HCV Entry Inhibitor (tentative talk title)***Thomas F. Baumert, M.D., Professor, Infectious Diseases, University of Strasbourg***2:40 Discovery and Characterization of a Class of Small Molecule HCV Entry Inhibitors***Carl J. Baldick, Ph.D., Senior Research Investigator, Infectious Diseases Research and Development, Bristol-Myers Squibb***3:10 Sponsored Presentations (Opportunity Available)****3:40 Networking Refreshment Break in Exhibit Hall with Poster Viewing****TOWARDS AN ALL ORAL REGIMEN****4:20 Combination DAA Strategies to Cure HCV***Speaker to be Announced, Idenix***4:50 Drug Resistance in DAA Combination Treatment***Christy Hebner, Ph.D., Research Scientist II, Gilead Sciences***5:20 Breakout Discussions****6:20 End of Day****6:30 – Evening Dinner Workshop: HCV and the Host Immune System (see page 3, separate registration required)****THURSDAY, APRIL 19****7:30 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee****DIRECT-ACTING ANTIVIRALS IN EARLY STAGE DEVELOPMENT****8:15 Chairperson's Opening Remarks****» 8:20 KEYNOTE PRESENTATION****ProTides as the Backbone of Anti-HCV Nucleoside Drug Discovery***Christopher McGuigan, Ph.D., Professor of Medicinal Chemistry, Pharmacy, Cardiff University***9:00 Discovery of BMS-791325, an Allosteric NS5B Replicase Inhibitor for the Treatment of Hepatitis C Virus***John Bender, Ph.D., Senior Scientist, Discovery Chemistry, Bristol-Myers Squibb***9:30 Discovery and Pre-Clinical Evaluation of Novel Inhibitors of HCV NS5B Polymerase***Ryan Craig Schoenfeld, Ph.D., Senior Scientist, Pharma Research & Early Development, Discovery Chemistry, Hoffman-La Roche, Inc.***10:00 Networking Coffee Break in the Exhibit Hall with Poster Viewing****10:45 Discovery of Potent Inhibitors of HCV that Interact with NS4B***Andrew J. Peat, Ph.D., Scientific Director, HCV Medicinal Chemistry, Infectious Diseases, GlaxoSmithKline***11:15 Follow-on NS5A Inhibitor, PPI-668***Leping Li, Ph.D., Associate Director, Chemistry, Presidio***11:45 Panel Discussion: Will there be an Ideal Anti-HCV Regimen?***Moderator: Christopher McGuigan, Ph.D., Professor of Medicinal Chemistry, Pharmacy, Cardiff University***12:15 pm Sponsored Presentation (Opportunity Available)****12:30 Walk and Talk Luncheon in the Exhibit Hall (Last Chance for Poster and Exhibit Viewing)****PROTEASE INHIBITORS****1:55 Chairperson's Remarks****2:00 Discovery of a Next-Generation NS3/4a Protease Inhibitor; Raising the Bar on this Important Class of Compounds***John McCauley, Ph.D., Senior Scientist, Infectious Diseases, Merck***2:30 HCV-Protease Inhibitors: Structure-Aided Design to the Clinic***Atul Agarwal, Ph.D., Executive Director, Computations, Achillion Pharmaceuticals***3:00 Networking Refreshment Break****3:20 Silencing HCV with a Potent and Selective Irreversible Protease Inhibitor***Deqiang Niu, Ph.D., Associate Director Medicinal Chemistry, Avila Therapeutics***3:50 Discovery and Validation of a Novel Allosteric Binding Site on the HCV NS3/4a Enzyme by Fragment-Based X-ray Screening***Andrew Woodhead, Ph.D., HCV Project Manager, Associate Director of Chemistry, Astex Therapeutics***4:20 Presentation to be Announced****4:50 End of Conference**

2011 Sponsors & Exhibitors:

Affina Biotechnologies
AMRI
ASINEX
Beta-Pro LLC
Agilent Life Sciences
(Formerly Biocius)
Blue Sky Biotech
BPS Bioscience
Caliper Life Sciences
ChemBridge Corporation
Chemical Computing Group
Cherokee Pharmaceuticals
Corning Incorporated
CovalX
Cubist Pharmaceuticals
Dotmatics Ltd.
Enamine LLC
ForteBio
GE Healthcare
Graffinity
ICx Nomadics
InterMed Discovery GmbH
Kalixsyn
KMT Hepatech Inc.
Lonza
MEDIT SA
Molplex
Netezza
NOVALIX SAS/Graffinity
Pharmaceuticals
Peakdale Molecular Ltd.
Pharmacore
Schrodinger
Selcia Ltd.
Simulations Plus Inc.

Sponsorship and Exhibit Information

Drug Discovery Chemistry presents your company with the opportunity to network with decision-makers and leading professionals from the global biotech and pharmaceutical community. By participating as a Sponsor, your company can identify new business leads, market new technology and increase brand awareness, while positioning your group as thought leaders among qualified buyers.

Sponsored Presentations

Showcase your technology to this highly-targeted group of decision makers. Package includes a 15 or 30-minute podium presentation within the scientific agenda, exhibit space, on-site branding and access to cooperative marketing efforts by CHI.

Breakfast & Luncheon Presentations

Opportunity includes a 30-minute podium presentation. Boxed lunches are delivered into the main session room, which guarantees audience attendance and participation. A limited number of presentations are available for sponsorship and they will sell out quickly. Sign on to secure your talk!

Invitation-Only VIP Dinner/Hospitality Suite

Sponsor will handpick their top prospects from the conference pre-registration list for an evening of networking at the hotel or a select local venue. CHI will extend invitations and deliver prospects. Evening will be customized according to sponsor's objectives:

- Purely social
- Focus group
- Reception style or plated dinner
- Plated Dinner with specific conversation focus

CHI Lead Generation:

CHI can help you with lead generation throughout the year. Our internal database includes over 800,000 prospects in the life sciences. By leveraging the database and mining for your specific requirements, we can produce multiple custom projects which will deliver your prospective buyers: Web Symposiums, Podcasts, White Papers, Custom Market Research Surveys and more!

Focus Groups

CHI will gladly provide you the opportunity of running a focus group on-site at Drug Discovery Chemistry. This exclusive gathering can be useful to conduct market research, gather feedback on a new product idea and gather marketing intelligence from industry experts on a specific topic.

User Group Meetings

Co-locate your user group meeting with Drug Discovery Chemistry. CHI will help market the event, manage logistical operations, develop the agenda, and more. CHI can handle the entire meeting, or components of your choosing.

Exhibit Information

Exhibitors will enjoy facilitated networking opportunities with qualified decision makers at Drug Discovery Chemistry, making it the perfect platform to launch a new product, collect feedback and generate new leads. Exhibit space sells out quickly, so reserve yours today!

How will CHI ensure that all delegates visit the exhibit hall?

- Providing several hours of dedicated Exhibit Hall visits
- Awarding fun raffle prizes inside the Exhibit Hall
- Providing reception and coffee breaks inside exhibit hall and promoting continuously

Additional Networking and Promotional Opportunities Include:

- Branded Badge Lanyards (exclusive)
- Exhibit Hall Reception
- Breakout Discussion Moderator
- Hotel Room Door Hanger (1 night exclusive)
- Hotel Room Drop
- Keynote Chair Drop
- Specific Conference Chair Drop
- Padfolio Sponsor
- Refreshment Break
- Branded Tote Bags
- Tote Bag Insert
- Program & Exhibit Guide Sponsor

For Sponsorship and Exhibit information, please contact:

Suzanne Carroll
Sr. Business Development Manager
781-972-5452
scarroll@healthtech.com

Hotel and Travel Information

Conference Hotel:

Hilton San Diego Resort & Spa

1775 East Mission Bay Drive

San Diego, CA 92109

Phone: 619-276-4010

Reservation line: 1-800-445-8667

Discounted Room Rate: \$199 s/d

Discounted Room Rate Cut-off Date: March 19, 2012

Please visit our conference website to make your reservations online or call the hotel directly to reserve your sleeping accommodations. You will need to identify yourself as a Cambridge Healthtech Institute conference attendee to receive the discounted room rate with the host hotel. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space-and-rate-availability basis. Rooms are limited, so please book early.

Flight Discounts:

Special discount rentals have been established with American Airlines for this conference.

- Call American Airlines 1-800-433-1790 use Conference code 1942AY.
- Go to www.aa.com/group enter Conference code 1942AY in promotion discount box
- Contact our dedicated travel agents at 1-877-559-5549 or chi@protravelinc.com.

Car Rental Discounts:

Special discount rentals have been established with Hertz for this conference. Please use one of the following methods:

- Call Hertz 1-800-654-3131 use our Hertz Convention Number (CV): 04KL0003
- Go online www.hertz.com use our Hertz Convention Number (CV): 04KL0003

